Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway

Fig. 4

The proliferation and glycolysis promoted by TG2 was attenuated by MEK inhibitor U0126. A and D The proliferation and glycolysis promoted by TG2 was attenuated by U0126 treatment. B The activation of p-MEK, p-ERK, LDHA and LDHB by overexpressed TG2 was rescued by U0126. C The mRNA level of LDHA and LDHB was detected by RT-qPCR. (* p<0.05, ** p<0.01)

Back to article page